Core Insights - The company, Hualu Bio (300970), reported a significant increase in industry scale and product variety since its listing, leading to a noticeable decline in the revenue proportion from enoki mushrooms [1] Group 1 - The company confirmed that its revenue from enoki mushrooms has decreased significantly as the scale and variety of its products have expanded post-listing [1] - The company emphasized the authenticity, accuracy, and completeness of its information disclosure, urging investors to rely on the disclosed information [1]

Core Insights - The company has experienced a positive first year since going public, aligning with expectations and hopes [1] - Increased visibility as a public entity has strengthened the company's performance and operational rigor [1] - The company's strategy is deemed effective, contributing to employee liquidity and overall positive outcomes [1]